Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva
Biosensors · 20.01.2023 · 13 (2) · 167
DOI: 10.3390/bios13020167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, online erschienen am 20.01.2023. Verfasst von Eiichi Tamiya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Photonics and Biosensing Open Innovation Laboratory, National Institute of Advanced Industrial Science and Technology, Photonics Center, Osa…. Hauptthemen laut MEDLINE: Biosensing Techniques, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, KAKENHI Grant-in-Aid for Scientific Research (B).
Abstract (Originalsprache)
Monitoring biomarkers is a great way to assess daily physical condition, and using saliva instead of blood samples is more advantageous as the process is simple and allows individuals to test themselves. In the present study, we analyzed the titers of neutralizing antibodies, IgG and secretory IgA (sIgA), in response to the SARS-CoV-2 vaccine, in saliva. A total of 19 saliva and serum samples were collected over a 10-month period 3 weeks after the first vaccine, 8 months after the second vaccine, and 1 month after the third vaccine. The ranges of antibody concentrations post-vaccination were: serum IgG: 81–15,000 U/mL, salivary IgG: 3.4–330 U/mL, and salivary IgA: 58–870 ng/mL. A sharp increase in salivary IgG levels was observed after the second vaccination. sIgA levels also showed an increasing trend. A correlation with trends in serum IgG levels was observed, indicating the possibility of using saliva to routinely assess vaccine efficacy. The electrochemical immunosensor assay developed in this study based on the gold-linked electrochemical immunoassay, and the antioxidant activity measurement based on luminol electrochemiluminescence (ECL), can be performed using portable devices, which would prove useful for individual-based diagnosis using saliva samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Photonics and Biosensing Open Innovation Laboratory, National Institute of Advanced Industrial Science and Technology, Photonics Center, Osaka University, 2-1 Yamadaoka, Suita 565-0871, Osaka, Japan.
- SANKEN, Osaka University, 8-1 Mihogaoka, Ibaraki 567-0047, Osaka, Japan.
- BioDevice Technology Ltd., 2-3 Asahidai, Nomi 923-1211, Ishikawa, Japan.
- Department of Environmental Pathology, Kanagawa Dental University, 82 Inaoka-cho, Yokosuka 238-0003, Kanagawa, Japan.
ORCID-Profile: Eiichi Tamiya, Shuto Osaki
Förderung
- Japan Society for the Promotion of Science
- KAKENHI Grant-in-Aid for Scientific Research (B)
Zitieren
APA
Tamiya, E., Osaki, S., Tsuchihashi, T., Ushijima, H., & Tsukinoki, K. (2023). Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva. Biosensors, 13(2), 167. https://doi.org/10.3390/bios13020167
Vancouver
Tamiya E, Osaki S, Tsuchihashi T, Ushijima H, Tsukinoki K. Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva. Biosensors. 2023;13(2):167. doi:10.3390/bios13020167
BibTeX
@article{Tamiya2023,
author = {Tamiya, Eiichi and Osaki, Shuto and Tsuchihashi, Tomoko and Ushijima, Hiromi and Tsukinoki, Keiichi},
title = {Point-of-Care Diagnostic Biosensors to Monitor Anti-SARS-CoV-2 Neutralizing IgG/sIgA Antibodies and Antioxidant Activity in Saliva},
journal = {Biosensors},
year = {2023},
volume = {13},
number = {2},
pages = {167},
doi = {10.3390/bios13020167}
}
EUVIMED